Compilation of a comprehensive gene panel for systematic assessment of genes that govern an individuals drug responses

Pharmacogenomics

Volumn 11, Issue 10, 2010, Pages 1403-1425

  Feng, Junjie ^a   Sun, Jielin ^a   Wang, Michael Zhuo ^b   Zhang, Zheng ^a   Kim, Seong Tae ^a   Zhu, Yi ^a   Sun, Jishan ^a   Xu, Jianfeng ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b University of North Carolina   (United States)

Author keywords

adverse drug reaction; efficacy n GWAS; pharmacodynamics; pharmacogenomics; pharmacokinetics

Indexed keywords

ABC TRANSPORTER; ACYL COENZYME A DEHYDROGENASE; ALDO KETO REDUCTASE; AMIDASE; AMINE OXIDASE (FLAVIN CONTAINING); ARACHIDONATE LIPOXYGENASE; BINDING PROTEIN; CARBONYL REDUCTASE; CYTOCHROME P450; EPOXIDE HYDROLASE; FLAVOPROTEIN; FLAVOPROTEIN PYRIDINE NUCLEOTIDE CYTOCHROME REDUCTASE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HYDROXYSTEROID DEHYDROGENASE; MICRORNA; OXIDOREDUCTASE; PEROXIDASE; PROSTAGLANDIN SYNTHASE; PROTEIN FMO; PROTEIN MT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RIBONUCLEOSIDE; RIBONUCLEOSIDE DISPHOSPHATE REDUCTASE; SECONDARY LYMPHOID TISSUE CHEMOKINE; STEROID 5ALPHA REDUCTASE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE; VASOPRESSIN; XENOBIOTIC AGENT;

ACETYLATION; ARTICLE; CARDIOTOXICITY; CYTOTOXICITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; DRUG UPTAKE; ENDOCYTOSIS; GENE FUNCTION; GENE IDENTIFICATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC ORGANIZATION; HUMAN; IMMUNOCYTOTOXICITY; NEUROTOXICITY; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM;

DATABASES, GENETIC; GENETIC ASSOCIATION STUDIES; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MICRORNAS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 78149348145     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.99     Document Type: Article

References (88)

1. Evans WE, Johnson JA: Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet. 2, 9-39 (2001).
2. Innocenti F, Ratain MJ: 'Irinogenetics' and UGT1A: from genotypes to haplotypes. Clin. Pharmacol. Ther. 75(6), 495-500 (2004).
3. Baynes RD, Gansert J: KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor effcacy in colorectal cancer. Am. J. Ther. 16(6), 554-561 (2009).
4. Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int. J. Clin. Pharmacol. Ther. 35(10), 401-413 (1997).
5. Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL: Goodman & Gilman's the Pharmacological Basis of Therapeutics. McGraw-Hill Medical Publishing Division, NY, USA (2005).
6. Harvey RA, Champe PC, Finkel R, Cubeddu LX, Clarke MA: Pharmacology. Lippincott Williams & Wilkins, PA, USA (2008).
7. Meibohm B, Wiley InterScience (Online service): Pharmacokinetics and Pharmacodynamics of Biotech Drugs Principles and Case Studies in Drug Development. Wiley-VCH, Weinheim, Germany, 403 (2006).
8. Modjtahedi H, Essapen S: Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 20(10), 851-855 (2009).
9. Hewett M, Oliver DE, Rubin DL et al.: PharmGKB: the pharmacogenetics knowledge base. Nucleic Acids Res. 30(1), 163-165 (2002).
10. Caldwell MD, Awad T, Johnson JA et al.: CYP4F2 genetic variant alters required warfarin dose. Blood 111(8), 4106-4112 (2008).
11. Penning TM, Petrash JM: Aldo-keto Reductases and Toxicant Metabolism. American Chemical Society, Washington, DC, USA (2004).
12. Knights KM, Sykes MJ, Miners JO: Amino acid conjugation: contribution to the metabolism and toxicity of xenobiotic carboxylic acids. Expert Opin. Drug Metab. Toxicol. 3(2), 159-168 (2007).
13. Knipp M: Metallothioneins and platinum(II) anti-tumor compounds. Curr. Med. Chem. 16(5), 522-537 (2009).
14. Lacana E, Amur S, Mummanneni P, Zhao H, Frueh FW: The emerging role of pharmacogenomics in biologics. Clin. Pharmacol. Ther. 82(4), 466-471 (2007).
15. Passetti F, Ferreira CG, Costa FF: The impact of microRNAs and alternative splicing in pharmacogenomics. Pharmacogenomics J. 9(1), 1-13 (2009).
16. Katzung BG: Basic & Clinical Pharmacology. McGraw-Hill Medical; McGraw-Hill [distributor], NY, USA (2007).
17. Xie W: Nuclear Receptors in Drug Metabolism. John Wiley & Sons, Hoboken, NJ, USA (2009).
18. Golan DE. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Wolters Kluwer Health/Lippincott Williams & Wilkins, PA, USA (2008).
19. Wishart DS, Knox C, Guo AC et al.: DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36(Database issue), D901-D906 (2008).
20. Griffths-Jones S, Saini HK, van Dongen S, Enright AJ: miRBase: tools for microRNA genomics. Nucleic Acids Res. 36(Database issue), D154-D158 (2008).
21. Li M, Li C, Guan W: Evaluation of coverage variation of SNP chips for genome-wide association studies. Eur. J. Hum. Genet. 16(5), 635-643 (2008).
22. Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ: Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat. Rev. Drug Discov. 7(1), 84-99 (2008).
23. Petzinger E, Geyer J: Drug transporters in pharmacokinetics. Naunyn Schmiedebergs Arch. Pharmacol. 372(6), 465-475 (2006).
24. Vasiliou V, Vasiliou K, Nebert DW: Human ATP-binding cassette (ABC) transporter family. Hum. Genomics 3(3), 281-290 (2009).
25. Pedersen MO, Larsen A, Stoltenberg M, Penkowa M: The role of metallothionein in oncogenesis and cancer prognosis. Prog. Histochem. Cytochem. 44(1), 29-64 (2009).
26. Awasthi YC, Sharma R, Yadav S, Dwivedi S, Sharma A, Awasthi S: The nonABC drug transporter RLIP76 (RALBP-1) plays a major role in the mechanisms of drug resistance. Curr. Drug Metab. 8(4), 315-323 (2007).
27. Zhang Y, Li M, Yao Q, Chen C: Roles and mechanisms of copper transporting ATPases in cancer pathogenesis. Med. Sci. Monit. 15(1), RA1-RA5 (2009).
28. Papadopoulos V, Baraldi M, Guilarte TR et al.: Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. 27(8), 402-409 (2006).
29. Steiner E, Holzmann K, Elbling L, Micksche M, Berger W: Cellular functions of vaults and their involvement in multidrug resistance. Curr. Drug Targets 7(8), 923-934 (2006).
30. Sanderson S, Emery J, Higgins J: CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-ana lysis. Genet. Med. 7(2), 97-104 (2005).
31. Goetz MP, Knox SK, Suman VJ et al.: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101(1), 113-121 (2007).
32. Mega JL, Close SL, Wiviott SD et al.: Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009).
33. Cashman JR, Zhang J: Human favin-containing monooxygenases. Annu. Rev. Pharmacol. Toxicol. 46, 65-100 (2006).
34. Gong B, Boor PJ: The role of amine oxidases in xenobiotic metabolism. Expert. Opin. Drug Metab. Toxicol. 2(4), 559-571 (2006).
35. Vasiliou V, Pappa A, Estey T: Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab. Rev. 36(2), 279-299 (2004).
36. Suga T: Drug metabolism in peroxisomes: involvement of peroxisomal b-oxidation system in the oxidative chain-shortening of xenobiotic acyl compounds. Drug Metab. Pharmacokinet. 18(3), 155-162 (2003).
37. Ito M, Ikeda Y, Arnez JG, Finocchiaro G, Tanaka K: The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. Biochim. Biophys. Acta. 1034(2), 213-218 (1990).
38. Jawien J, Gajda M, Rudling M et al.: Inhibition of fve lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur. J. Clin. Invest. 36(3), 141-146 (2006).
39. Gao J, Xiong Y, Ho YS et al.: Glutathione peroxidase 1-defcient mice are more susceptible to doxorubicin-induced cardiotoxicity. Biochim. Biophys. Acta, 1783(10), 2020-2029 (2008).
40. Lu W, Uetrecht JP: Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin. Drug Metab. Dispos. 36(8), 1624-1636 (2008).
41. Nagasaka A, Hidaka H: Effect of antithyroid agents 6-propyl-2-thiouracil and 1-methyl-2-mercaptoimidazole on human thyroid iodine peroxidase. J. Clin. Endocrinol. Metab. 43(1), 152-158 (1976).
42. Haglund S, Taipalensuu J, Peterson C, Almer S: IMPDH activity in thiopurine-treated patients with infammatory bowel disease-relation to TPMT activity and metabolite concentrations. Br. J. Clin. Pharmacol. 65(1), 69-77 (2008).
43. Smith MA, Marinaki AM, Arenas M et al.: Novel pharmacogenetic markers for treatment outcome in azathioprine-treated infammatory bowel disease. Aliment Pharmacol. Ther. 30(4), 375-384 (2009).
44. Kim YI: Role of the MTHFR polymorphisms in cancer risk modifcation and treatment. Future Oncol. 5(4), 523-542 (2009).
45. Barski OA, Tipparaju SM, Bhatnagar A: The aldo-keto reductase superfamily and its role in drug metabolism and detoxifcation. Drug Metab. Rev. 40(4), 553-624 (2008).
46. Oppermann U: Carbonyl reductases: the complex relationships of mammalian carbonyl-and quinone-reducing enzymes and their role in physiology. Annu. Rev. Pharmacol. Toxicol. 47, 293-322 (2007).
47. Uetrecht J: N-oxidation of drugs associated with idiosyncratic drug reactions. Drug Metab. Rev. 34(3), 651-665 (2002).
48. Martinez VG, Williams KJ, Stratford IJ, Clynes M, O'Connor R: Overexpression of cytochrome P450 NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fuorouracil: possible mechanisms involved. Toxicol. In vitro 22(3), 582-588 (2008).
49. Cerqueira NM, Fernandes PA, Ramos MJ: Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry 13(30), 8507-8515 (2007).
50. Hatfeld JM, Wierdl M, Wadkins RM, Potter PM: Modifcations of human carboxylesterase for improved prodrug activation. Expert Opin. Drug Metab. Toxicol. 4(9), 1153-1165 (2008).
51. Furlong CE: Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds. J. Biochem. Mol. Toxicol. 21(4), 197-205 (2007).
52. Decker M, Arand M, Cronin A: Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch. Toxicol. 83(4), 297-318 (2009).
53. Sperker B, Backman JT, Kroemer HK: The role of b-glucuronidase in drug disposition and drug targeting in humans. Clin. Pharmacokinet. 33(1), 18-31 (1997).
54. Kauffman FC, Sharp S, Allan BB, Burchell A, Coughtrie MW: Microsomal steroid sulfatase: interactions with cytosolic steroid sulfotransferases. Chem. Biol. Interact. 109(1-3), 169-182 (1998).
55. Krynetski E, Evans WE: Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 22(47), 7403-7413 (2003).
56. Knights KM: Role of hepatic fatty acid:coenzyme A ligases in the metabolism of xenobiotic carboxylic acids. Clin. Exp. Pharmacol. Physiol. 25(10), 776-782 (1998).
57. Authier F, Mort JS, Bell AW, Posner BI, Bergeron JJ: Proteolysis of glucagon within hepatic endosomes by membrane-associated cathepsins B and D. J. Biol. Chem. 270(26), 15798-15807 (1995).
58. Authier F, Danielsen GM, Kouach M, Briand G, Chauvet G: Identifcation of insulin domains important for binding to and degradation by endosomal acidic insulinase. Endocrinology 142(1), 276-289 (2001).
59. Yamahara H, Morimoto K, Lee VH, Kim KJ: Effects of protease inhibitors on vasopressin transport across rat alveolar epithelial cell monolayers. Pharm. Res. 11(11), 1617-1622 (1994). (Pubitemid 24339684)
60. Lee TY, Tjin Tham Sjin RM, Movahedi S et al.: Linking antibody Fc domain to endostatin signifcantly improves endostatin half-life and effcacy. Clin. Cancer Res. 14(5), 1487-1493 (2008).
61. Smedsrod B, Einarsson M: Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver. Thromb. Haemost. 63(1), 60-66 (1990).
62. Bu G, Williams S, Strickland DK, Schwartz AL: Low density lipoprotein receptor-related protein/a 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc. Natl Acad. Sci. USA 89(16), 7427-7431 (1992).
63. Kostenis E: G proteins in drug screening: from ana lysis of receptor-G protein specifcity to manipulation of GPCR-mediated signalling pathways. Curr. Pharm. Des. 12(14), 1703-1715 (2006).
64. Camerino DC, Tricarico D, Desaphy JF: Ion channel pharmacology. Neurotherapeutics 4(2), 184-198 (2007).
65. Zhu Y, Hu J, Hu Y, Liu W: Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance. Cancer Treat. Rev. 35(7), 590-596 (2009).
66. Riely GJ, Pao W, Pham D et al.: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with geftinib or erlotinib. Clin. Cancer Res. 12(3 Pt 1), 839-844 (2006).
67. Plesec TP, Hunt JL: KRAS mutation testing in colorectal cancer. Adv. Anat. Pathol. 16(4), 196-203 (2009).
68. Toler SM: Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy. Exp. Biol. Med. (Maywood) 229(7), 607-615 (2004).
69. Conklin KA: Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr. Cancer Ther. 3(4), 294-300 (2004).
70. Ronaldson KJ, McNeil JJ: Improving drug safety by locating genetic markers for hypersensitivity reactions. Med. J. Aust. 190(11), 641-643 (2009).
71. Segura-Bruna N, Rodriguez-Campello A, Puente V, Roquer J: Valproate-induced hyperammonemic encephalopathy. Acta Neurol. Scand. 114(1), 1-7 (2006).
72. Roden DM: Cellular basis of drug-induced torsades de pointes. Br. J. Pharmacol. 154(7), 1502-1507 (2008).
73. Takeuchi F, McGinnis R, Bourgeois S et al.: A genome-wide association study confrms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), e1000433 (2009).
74. Cooper GM, Johnson JA, Langaee TY et al.: A genome-wide scan for common genetic variants with a large infuence on warfarin maintenance dose. Blood 112(4), 1022-1027 (2008).
75. Teichert M, Eijgelsheim M, Rivadeneira F et al.: A genome-wide association study of acenocoumarol maintenance dosage. Hum. Mol. Genet. 18(19), 3758-3768 (2009).
76. Cui J, Taylor KE, Destefano AL et al.: Genome-wide association study of determinants of anti-cyclic citrullinated peptide antibody titer in adults with rheumatoid arthritis. Mol. Med. 15(5-6), 136-143 (2009).
77. Tanaka Y, Nishida N, Sugiyama M et al.: Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009).
78. Ge D, Fellay J, Thompson AJ et al.: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
79. Suppiah V, Moldovan M, Ahlenstiel G et al.: IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat. Genet. 41(10), 1100-1104 (2009).
80. Shuldiner AR, O'Connell JR, Bliden KP et al.: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical effcacy of clopidogrel therapy. JAMA 302(8), 849-857 (2009).
81. Liu C, Batliwalla F, Li W et al.: Genome-wide association scan identifes candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 14(9-10), 575-581 (2008).
82. Yang JJ, Cheng C, Yang W et al.: Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301(4), 393-403 (2009).
83. Daly AK, Donaldson PT, Bhatnagar P et al.: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to fucloxacillin. Nat. Genet. 41(7), 816-819 (2009).
84. Link E, Parish S, Armitage J et al.: SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008).
85. Volpi S, Heaton C, Mack K et al.: Whole genome association study identifes polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol. Psychiatry 14(11), 1024-1031 (2009).
86. Kindmark A, Jawaid A, Harbron CG et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8(3), 186-195 (2008).
87. Sarasquete ME, Garcia-Sanz R, Marin L et al.: Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism ana lysis. Blood 112(7), 2709-2712 (2008).
88. Conrad DF, Pinto D, Redon R et al.: Origins and functional impact of copy number variation in the human genome. Nature 464(7289), 704-712 (2010).